Cryoport Inc. (CYRX)
Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
Here is how CryoPort, Inc. (CYRX) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
CryoPort (CYRX) Upgraded to Buy: Here's Why
CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
CryoPort Q2 Earnings Call Highlights
CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million.
CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago.
Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.22 per share a year ago.
Cryoport: Moving Toward Commercial Scalability And Near-Term Breakeven
Cryoport receives a buy rating with a $9.1 price target, implying 17% upside by FY 2026. CYRX demonstrated double-digit revenue growth in Q4 2025, led by Life Sciences Services, and improved gross margins to 47.8%. Management targets positive adjusted EBITDA in H2 2026, supported by cost reductions and a strengthened partnership with DHL.
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.42 per share a year ago.
Cryoport, Inc. (CYRX) Q3 2025 Earnings Call Transcript
Cryoport, Inc. ( CYRX ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief Administrative Officer Mark W. Sawicki - Senior VP & Chief Scientific Officer Thomas Heinzen - Vice President of Corporate Development & Investor Relations Conference Call Participants Todd Fromer - Kanan, Corbin, Schupak & Aronow, Inc. Kyle Crews - UBS Investment Bank, Research Division David Saxon - Needham & Company, LLC, Research Division Puneet Souda - Leerink Partners LLC, Research Division Matthew Stanton - Jefferies LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division David Larsen - BTIG, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Presentation Operator " Jerrell Shelton Chairman, President & CEO " Robert Stefanovich Senior VP, CFO, Treasurer & Chief Administrative Officer " Mark W.
CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.02 per share a year ago.
